Pharma Pulse 10/28/24: Operating Without a Commercial Blueprint, The Dilemma of Childhood Vaccines Post Pandemic & more

Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches

How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.

The Dilemma of Childhood Vaccines Post Pandemic

With the end of the PREP Act Provisions in sight, pharmacists should Reflect on their impact and plan to continue them.

Government ‘Guardrails’ for A.I. Tools

A national security memorandum detailed how agencies should streamline operations with artificial intelligence safely.

President Biden has released a series of documents that grapple with the challenges of using A.I. tools to speed up government operations.

LabGenomics USA Completes Acquisition of IMD CLIA Labs

LabGenomics USA has successfully acquired Integrated Molecular Diagnostics (IMD) CLIA labs, bringing the total number of its CLIA-certified labs in the U.S. to four. This acquisition strengthens LabGenomics’ strategic development and expands its diagnostic services nationwide, particularly in molecular technology.

Marissa Romano, MS, PA-C on LinkedIn

Illicit actors should be the true target of scrutiny and legal action but instead other organizations seemingly lump together compound pharmacies and illicit actors when it comes to "counterfeits" and "copycats".

We know exactly why that rhetoric exists and APC's constant fight to correct the language and identify the TRUE illicit entities is extremely significant. Credible and verified compound pharmacies and facilities are integral to patient care and well-being!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs